



Sheet 1 of 6

1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	ATTORNEY DOCKET NO.	2488-1-012PCT/US
	SERIAL NO.	10/558,937
	APPLICANT	Miles Andrew NUNN
	FILING DATE	December 1, 2005
	GROUP	Not yet assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
/H.A.R./	BA	WO 93/17099	9/2/93	PCT			

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

/H.A.R./	CA	Bao et al., Transgenic Expression of a Soluble Complement Inhibitor Protects Against Renal Disease and Promotes Survival in MRL/lpr Mice, J. Immunol., 168:3601-3607 (2002)
↓	CB	Bedford et al., Influence of complement depletion on sperm function in the female rabbit, J. Reprod. Fert., 69:523-528 (1993)
↓	CC	Biesecker et al., Derivation of RNA aptamer inhibitors of human complement C5, Immunopharmacology, 42:219-230 (1999)
↓	CD	Cicchetti et al., Combined Inhibition of Apoptosis and Complement Improves Neural Graft Survival of Embryonic Rat and Porcine Mesencephalon in the Rat Brain, Exp. Neurol., 177:376-384 (2002)

EXAMINER: /Hope Robinson/	DATE CONSIDERED: 04/11/2009
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 IRSY. 7.801
U.S. Department of Commerce
Patent and Trademark Office

ATTORNEY
DOCKET
NO.

2488-1-012PCT/US

SERIAL NO.

10/558,937

APPLICANT

Miles Andrew NUNN

FILING
DATE

December 1, 2005

GROUP

Not yet assigned

LIST OF DOCUMENTARY INFORMATION
CITED BY APPLICANT
(Use several sheets if necessary)

/H.A.R./	CE	Diamond et al., Human CD59 expressed in transgenic mouse hearts inhibits the activation of complement, 3:305-312 (1995)
_____	CF	Emmer et al., Characterization of Complement Anaphylatoxins and Their Biological Responses, In: The Human Complement System in Health and Disease, Volantakis, J.G., Frank, M.W. (Eds.), Marcel Dekker, New York, 841-864
/H.A.R./	CG	Fecke et al., Protection of hDAF-transgenic porcine endothelial cells against activation by human complement: role of the membrana attack complex, Xenotransplantation, 9:97-105 (2002)
	CH	Fiorante et al., Low molecular weight dextran sulfate prevents complement activation and delays hyperacute rejection in pig-to-human xenotransplantation models, Xenotransplantation, 8:24-35 (2001)
	CI	Fitch et al., Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass, Circulation, 100:2499-2506 (1999)
	CJ	Frei et al., Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-C5 antibodies, Molecular Cell. Probes, 1:141-149 (1987)
	CK	Giclas, P.C., Classical pathway evaluation and alternative pathway evaluation (sections 13.1. and 13.2), In: Current Protocols in Immunology, Editors: J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach and W. Strober, Vol. 3 (1994)
	CL	Homeister et al., Effects of Complement Activation in the Isolated Heart, Circulation Research, 71:303-319 (1992)
	CM	Hebelle et al., Suppression of the Immune Response by a Soluble Complement Receptor of B Lymphocytes, 254:102-105 (1991)
	CN	Jarvis et al., IgM rheumatoid factor and the inhibition of covalent binding of C4b to IgG in immune complexes, Clin. Exp. Rheumatol., 11:135-141 (1993)
↓	CO	Kohl, Anaphylatoxins and infectious and non-infectious inflammatory diseases, Molecular Immunology, 38:175-187 (2001)


EXAMINER: /Hope Robinson/

DATE CONSIDERED: 04/11/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609;
Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Hope Robinson 6/11/10

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	2488-I-012PCT/US
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	SERIAL NO.	10/558,937
	APPLICANT	Miles Andrew NUNN
	FILING DATE	December 1, 2005
	GROUP	Not yet assigned

/H.A.R./	CP	Kontinen et al., Complement In acute and chronic arthritides: assessment of C3c, C9 and protectin (CD59) in synovial membrane, Ann. Rheum. Dis., 55:888-894 (1996)
	CQ	Kroshus et al., A recombinant soluble chimeric complement inhibitor composed of human CD46 and CD55 reduces acute cardiac tissue injury in models of pig-to-human heart transplantation, Transplantation, 69:2282-2289 (2000)
	CR	Link et al., Selection of phage-displayed anti-guinea pig C5 or C5a antibodies and their application in xenotransplantation, Mol. Immunol., 36:1235-1247 (1999)
	CS	Miletic, et al., Complement activation in stored platelet concentrates, Transfusion, 33:150-154 (1993)
	CT	Mulligan et al., Endothelial Targeting and Enhanced Antiinflammatory Effects of Complement Inhibitors Possessing Sialyl Lewis ^x Moieties, J. Immunol., 162:4952-4959 (1999)
	CU	Paesen et al., Tick Histamine-Binding Proteins: Isolation, Cloning, and Three-Dimensional Structure, Molecular Cell, 3:661-671 (1999)
	CV	Paesen et al., Tick histamine-binding proteins: lipocalins with a second binding cavity, Biochim. Biophys. Acta., 1482:92-101 (2000)
	CW	Pratt et al., Effects of Complement Inhibition with Soluble Complement Receptor-1 on Vascular Injury and Inflammation during Renal Allograft Rejection in the Rat, Am. J. Pathol., 149:2055-2066 (1996)
	CX	Rehrig et al., Complement Inhibitor, Complement Receptor 1-Related Gene/Protein y-Ig Attenuates Intestinal Damage After the Onset of Mesenteric Ischemia/Reperfusion Injury in Mice, J. Immunol., 167:5921-5927 (2001)
	CY	Ribeiro, Ixodes dammini: Salivary Anti-complement Activity, Exp. Parasitol., 64:347-353 (1987)
	CZ	Rollins et al., Retroviral Vector Producer Cell Killing in Human Serum Is Mediated by Natural Antibody and Complement: Strategies for Evading the Humoral Immune Response, Hum. Gene Ther., 7:619-626 (1996)

EXAMINER: /Hope Robinson/	DATE CONSIDERED: 04/11/2009
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	





Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	ATTORNEY DOCKET NO.	2488-1-012PCT/US
	SERIAL NO.	10/558,937
	APPLICANT	Miles Andrew NUNN
	FILING DATE	December 1, 2005
	GROUP	Not yet assigned

/H.A.R./	DA	Rollins et al., Anti-C5 Single Chain Antibody Therapy Blocks Complement & Leukocyte Activation and Reduces Myocardial Tissue Damage in CPB Patients, <i>Mol. Immunol.</i> , 35:397-397 (1998)
	DB	Sahu et al., Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics, <i>Immunopharmacology</i> , 49:133-148 (2000)
	DC	Sandoval et al., Distal Recognition Site for Classical Pathway Convertase Located in the C345C/Natrin Module of Complement Component C5, <i>The Journal of Immunol.</i> , 165:1068-1073 (2000)
	DD	Schiller et al., Expression of a Soluble Complement Inhibitor Protects Transgenic Mice from Antibody-Induced Acute Renal Failure, <i>J. Am. Soc. Nephrol.</i> , 12:71-79 (2001)
	DE	Smith et al., Membrane-targeted complement inhibitors, <i>Mol. Immunol.</i> , 38:249-255 (2001)
	DF	Solomon et al., Transmission of antibody-induced arthritis is independent of complement component 4(C4) and the complement receptors 1 and 2 (CD21/35), <i>Eur. J. Immunol.</i> , 32:644-651 (2002)
	DG	Tanaka et al., Effect of Anticomplement Agent K76 COOH On Hamster-To-Rat and Guinea Pig-to-Rat Heart Xenotransplantation, <i>Transplantation</i> , 62:681-688 (1996)
	DH	Thomas et al., Sulfonated Dextran Inhibits Complement Activation and Complement-Dependent Cytotoxicity in an <i>in vitro</i> Model of Hyperacute Xenograft Rejection, <i>Mol. Immunol.</i> , 33:643-648 (1996)
	DI	Vakeva et al., Myocardial Infarction and Apoptosis After Myocardial Ischemia and Reperfusion-Role of the Terminal Complement Components and Inhibition by Anti-C5 Therapy, <i>Circulation</i> , 97:2259-2267 (1998)
	DJ	Valenzuela et al., Purification, Cloning, and Expression of a Novel Salivary Anticomplement Protein from the Tick, <i>Ixodes scapularis</i> , <i>J. Biol. Chem.</i> , 275:18717-18723 (2000)
↓	DK	Wang et al., Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease, <i>Proc. Natl. Acad. Sci. USA</i> , 92:8955-8959 (1995)

EXAMINER: /Hope Robinson/	DATE CONSIDERED: 04/11/2009
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	2488-1-012PCT/US
	SERIAL NO.	10/558,937
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	Miles Andrew NUNN
	FILING DATE	December 1, 2005
	GROUP	Not yet assigned

/H.A.R./	DL	Wang et al., Amelioration of lupus-like autoimmune disease in NZB/WF ₁ mice after treatment with a blocking monoclonal antibody specific for complement component C5, <i>Proc. Natl. Acad. Sci. USA</i> , 93:8563-8568 (1996)
	DM	Ward et al., Use of Animal Models to Define Complement Functions, In: <i>Contemporary Immunology: Therapeutic Interventions in the Complement System</i> , Lambris, J.D., Holers, V.M. (Eds.), Humana Press, Totowa, NJ, 237-253 (2000)
	DN	Weisman et al., Soluble Human Complement Receptor Type 1: <i>In vivo</i> Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and Necrosis, <i>Science</i> , 249:146-151 (1990)
	DO	Wyss-Coray et al., Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice, <i>Proc. Natl. Acad. Sci. USA</i> , 99:10837-10842 (2002)
	DP	Zhang et al., Targeting of Functional Antibody-Decay-accelerating Factor Fusion Proteins to a Cell Surface, <i>J. Biol. Chem.</i> , 276:27290-27295 (2001)
	DQ	McKenzie et al., Regulation of Complement Activity by Vaccinia Virus Complement-Control Protein, <i>J. of Infectious Diseases</i> , 166:1245-1250 (1992)
	DR	Asghar et al., Inhibition of Complement by a Series of Substituted 2-Aryl-1, 3-Indandiones: Interaction with the Fifth Component of Complement, <i>Molecular Immunology</i> , 23:459-465 (1986)
	DS	White, Jr. et al., Suppression of mouse complement activity by contaminants of technical grade pentachlorophenol, <i>Agents and Actions</i> , 16:385-392 (1985)
	DT	Feuillard et al., Comparative study of <i>in vitro</i> inhibition of activation of the classical and alternative pathways of human complement by the magnesium and sodium salts of the anti-inflammatory peptide N-acetyl-aspartyl-glutamic acid (NAAGA), <i>Agents and Actions</i> , 32:343-346 (1991)
↓	DU	Baranda et al., Purification, N-terminal sequencing and diagnostic value of the major antigens of <i>Ornithodoros erraticus</i> and <i>O. moubata</i> , <i>Veterinary Parasitology</i> , 97:193-206 (2000)

EXAMINER: /Hope Robinson/	DATE CONSIDERED: 04/11/2009
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	ATTORNEY DOCKET NO.	2488-1-012PCT/US
	SERIAL NO.	10/558,937
	APPLICANT	Miles Andrew NUNN
	FILING DATE	December 1, 2005
	GROUP	Not yet assigned

[illegible]

EXAMINER:	/Hope Robinson/	DATE CONSIDERED:	04/11/2009
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			